B-intervention	0	9	Melatonin
O	10	13	for
O	14	24	Prevention
O	25	27	of
O	28	34	Breast
B-condition	35	44	Radiation
I-condition	45	55	Dermatitis
O	55	56	:
O	57	58	A
O	59	64	Phase
O	65	67	II
O	67	68	,
O	69	80	Prospective
O	80	81	,
O	82	88	Double
O	88	89	-
O	89	94	Blind
O	95	105	Randomized
O	106	111	Trial
O	111	112	.

O	113	122	Radiation
O	122	123	-
O	123	130	induced
O	131	141	dermatitis
O	142	144	is
O	145	153	commonly
O	154	158	seen
O	159	165	during
O	166	178	radiotherapy
O	179	182	for
O	183	189	breast
O	190	196	cancer
O	196	197	.

O	198	207	Melatonin
O	207	208	-
O	208	213	based
O	214	220	creams
O	221	225	have
O	226	231	shown
O	232	233	a
O	234	244	protective
O	245	251	effect
O	252	259	against
O	260	271	ultraviolet
O	271	272	-
O	272	279	induced
O	280	288	erythema
O	289	292	and
O	293	294	a
O	295	310	radioprotective
O	311	317	effect
O	318	320	in
O	321	325	rats
O	325	326	.

O	327	329	To
O	330	338	evaluate
O	339	342	the
O	343	351	efficacy
O	352	354	of
O	355	364	melatonin
O	364	365	-
O	365	375	containing
O	376	381	cream
O	382	384	in
O	385	395	minimizing
O	396	401	acute
O	402	411	radiation
O	412	422	dermatitis
O	422	423	.

O	424	426	In
O	427	431	this
O	432	437	phase
O	438	440	II
O	440	441	,
O	442	453	prospective
O	453	454	,
O	455	465	randomized
O	465	466	,
O	467	474	placebo
O	474	475	-
O	475	485	controlled
O	486	492	double
O	492	493	-
O	493	498	blind
O	499	504	study
O	504	505	,
B-eligibility	506	514	patients
I-eligibility	515	518	who
I-eligibility	519	528	underwent
I-eligibility	529	535	breast
I-eligibility	535	536	-
I-eligibility	536	546	conserving
I-eligibility	547	554	surgery
I-eligibility	555	558	for
I-eligibility	559	564	stage
I-eligibility	565	566	0
I-eligibility	566	567	-
I-eligibility	567	568	2
I-eligibility	569	575	breast
I-eligibility	576	582	cancer
O	583	587	were
O	588	596	randomly
O	597	606	allocated
O	607	609	to
O	610	619	melatonin
O	620	628	emulsion
O	629	630	(
B-intervention-participants	630	632	26
O	633	638	women
O	638	639	)
O	640	642	or
B-control	643	650	placebo
O	651	652	(
B-control-participants	652	654	21
O	655	660	women
O	660	661	)
O	662	665	for
O	666	671	twice
O	672	677	daily
O	678	681	use
O	682	688	during
O	689	698	radiation
O	699	708	treatment
O	709	712	and
O	713	714	2
O	715	720	weeks
O	721	730	following
O	731	734	the
O	735	738	end
O	739	741	of
O	742	754	radiotherapy
O	754	755	.

O	756	759	All
O	760	765	women
O	766	774	received
O	775	777	50
O	778	780	Gy
O	781	786	whole
O	787	793	breast
O	794	803	radiation
O	804	811	therapy
O	812	816	with
O	817	818	2
O	819	821	Gy
O	821	822	/
O	822	824	fx
O	825	830	using
O	831	839	computed
O	840	850	tomography
O	850	851	-
O	851	856	based
O	857	859	3D
O	860	868	planning
O	868	869	.

O	870	878	Patients
O	879	883	were
O	884	892	examined
O	893	896	and
O	897	906	completed
O	907	908	a
O	909	917	detailed
O	918	931	questionnaire
O	932	938	weekly
O	939	942	and
O	943	944	2
O	945	950	weeks
O	951	960	following
O	961	964	the
O	965	968	end
O	969	971	of
O	972	981	treatment
O	981	982	.

O	983	986	The
O	987	997	occurrence
O	998	1000	of
B-outcome	1001	1006	grade
I-outcome	1007	1008	1
I-outcome	1008	1009	/
I-outcome	1009	1010	2
I-outcome	1011	1016	acute
I-outcome	1017	1026	radiation
I-outcome	1027	1037	dermatitis
O	1038	1041	was
O	1042	1055	significantly
O	1056	1061	lower
O	1062	1063	(
B-iv-bin-percent	1063	1065	59
I-iv-bin-percent	1065	1066	%
O	1067	1069	vs
O	1069	1070	.
B-cv-bin-percent	1071	1073	90
I-cv-bin-percent	1073	1074	%
O	1074	1075	,
O	1076	1077	P
O	1078	1079	=
O	1080	1081	0
O	1081	1082	.
O	1082	1085	038
O	1085	1086	)
O	1087	1089	in
O	1090	1093	the
O	1094	1103	melatonin
O	1104	1109	group
O	1109	1110	.

O	1111	1116	Women
O	1117	1122	older
O	1123	1127	than
O	1128	1130	50
O	1131	1134	had
O	1135	1148	significantly
O	1149	1153	less
B-outcome	1154	1164	dermatitis
O	1165	1169	than
O	1170	1177	younger
O	1178	1186	patients
O	1187	1188	(
B-iv-bin-percent	1188	1190	56
I-iv-bin-percent	1190	1191	%
O	1192	1194	vs
O	1194	1195	.
B-cv-bin-percent	1196	1199	100
I-cv-bin-percent	1199	1200	%
O	1200	1201	,
O	1202	1203	P
O	1204	1205	=
O	1206	1207	0
O	1207	1208	.
O	1208	1211	021
O	1211	1212	)
O	1212	1213	.

O	1214	1217	The
B-outcome	1218	1225	maximal
I-outcome	1226	1235	radiation
I-outcome	1236	1246	dermatitis
O	1247	1249	in
O	1250	1253	the
O	1254	1259	study
O	1260	1265	group
O	1266	1269	was
B-outcome	1270	1275	grade
I-outcome	1276	1277	2
O	1278	1280	in
B-iv-bin-percent	1281	1283	15
I-iv-bin-percent	1283	1284	%
O	1285	1287	of
O	1288	1291	the
O	1292	1299	treated
O	1300	1308	patients
O	1308	1309	.

O	1310	1318	Patients
O	1319	1326	treated
O	1327	1331	with
O	1332	1341	melatonin
O	1341	1342	-
O	1342	1352	containing
O	1353	1361	emulsion
O	1362	1373	experienced
O	1374	1387	significantly
O	1388	1395	reduced
O	1396	1405	radiation
O	1406	1416	dermatitis
O	1417	1425	compared
O	1426	1428	to
O	1429	1437	patients
O	1438	1447	receiving
O	1448	1455	placebo
O	1455	1456	.
